Barr Seeks FDA Approval Of Low-Dose Extended-Cycle Contraceptive Lo Seasonique
This article was originally published in The Pink Sheet Daily
FDA grants Lo Seasonique an Oct. 24 action date.
You may also be interested in...
Wyeth’s oral contraceptive is the first continuous-use product without a placebo phase or pill-free interval.
Company tries to hedge losses through “authorized” generic and follow-on Seasonique.
A Phase III trial testing dapagliflozin in chronic kidney disease patients with and without diabetes was stopped early following a recommendation from an independent data monitoring committee.